Publications

Daud AI. BEAM trial: lighting the way ahead? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. PMID: 22124100


Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Familial concordance for height and its components: analyses from the Breakthrough Generations Study. American journal of human biology : the official journal of the Human Biology Council. 2011. PMID: 22121080


Hua-Xin Gao, Shawn Anderson, Lingjing Chen, Cigall Kadoch, Byron C Hann, Clifford Lowell, Colin Collins, James L. Rubenstein. Genomic and Molecular Properties of Relapsed CNS Lymphoma Using Novel Primary Meningeal Lymphoma Cell Lines and Intracranial Xenografts,. Blood. 2011. PMID:


Catherine C. Smith, Alexander E Perl, Elisabeth Lasater, Chao Zhang, Grace R Jeschke, Lauren E. Damon, Martin Carroll, Neil P. Shah. PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro. Blood. 2011. PMID:


Anna Bet-Lachin, Frank Jiang, Lingjing Chen, Keyvan Keshari, David Wilson, John Kurhanewicz, James L. Rubenstein. Metabolic Profiling of CNS Lymphoma and Its Microenvironment. Blood. 2011. PMID:


James L. Rubenstein, Lingjing Chen, Ranjana Advani, Jan Drappatz, Elizabeth Gerstner, Tracy Batchelor, Hendrikus Krouwer, Cigall Kadoch, Pamela Munster, Soonmee Cha, Marc A Shuman, Lloyd E. Damon. Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. Blood. 2011. PMID:


Catherine C. Smith, Michael Brown, Jason Chin, Corynn Kasap, Sara Salerno, Lauren E. Damon, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric Schadt, Neil Shah. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,. Blood. 2011. PMID:


Catherine C. Smith, Jason Chin, Qi Wang, Sara Salerno, Lauren E. Damon, Jeremy P. Hunt, Mark J. Levis, Alexander E Perl, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric Schadt, John Kuriyan, Neil Shah. Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia. Blood. 2011. PMID:


Liu H, Johnson JL, Koval G, Malnassy G, Sher D, Damon LE, Hsi ED, Bucci DM, Linker CA, Cheson BD, Stock W. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2011. PMID: 22102709


Jorge E. Cortes, Alexander E Perl, Catherine C. Smith, Tibor Kovacsovics, Herve Dombret, Hartmut Dohner, Bjorn Steffen, Arnaud Pigneux, Philippe Rousselot, Juergen Krauter, Giovanni Martinelli, Elihu H. Estey, Alan K Burnett, Anthony D. Ho, Norbert Ifrah, Theo de Witt, Robert Corringham, Joyce James, David Lilienfeld, Eugen Leo, Guy Gammon, Mark J. Levis. A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results. Blood. 2011. PMID:


Francisco Valles, Samuel Regalado, James L. Rubenstein, Soonmee Cha. Combined Diffusion and Perfusion MRI As Biomarkers of Prognosis in Immunocompetent Patients with Primary CNS Lymphoma. Blood. 2011. PMID:


Warren Fiskus, Catherine C. Smith, Jacqueline Smith, Scott C. Wise, Elisabeth Lasater, Lauren E. Damon, Sara Salerno, Allan Fleming, Ruben Reyes, Siddhartha Ganguly, Mark S. Berger, Tom J. Rutkoski, Joseph McGuirk, Neil Shah, Kapil N. Bhalla. Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations. Blood. 2011. PMID:


Cigall Kadoch, Valerie Wong, Lingjing Chen, Anna Bet-Lachin, Ritu Roy, William Hyun, Caroline Behler, Clifford Lowell, James L. Rubenstein. Dynamic Changes in Macrophage Polarization Correlate with Progression and Response in CNS Lymphoma: Insights Into the Transcriptome of Lymphoma-Associated M2 Macrophages,. Blood. 2011. PMID:


Catherine C. Smith, Lauren E. Damon, Xiaotian Zhu, Sara Salerno, Neil Shah. Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants. Blood. 2011. PMID:


Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D'Andrea K, Attiyeh EF, Simon MC, Nathanson KL. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer research. 2011. PMID: 22094876


Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2011. PMID: 22083023


Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, Chan TA. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America. 2011. PMID: 22065749


Naidus E, Damon L, Schwartz BS, Breed C, Liu C. Experience with use of Zostavax(®) in patients with hematologic malignancy and hematopoietic cell transplant recipients. American journal of hematology. 2011. PMID: 22052650


Huang V, Place RF, Portnoy V, Wang J, Qi Z, Jia Z, Yu A, Shuman M, Yu J, Li LC. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic acids research. 2011. PMID: 22053081